Rhinosinusitis

The EUFOREA allergic rhinitis patient portal is an expert-led online resource designed to provide clear, reliable, and accessible information to people living with allergic rhinitis. Developed as part of EUFOREA’s broader patient initiatives, the portal aims to empower patients through education, support informed decision-making, and encourage active participation in their own care.

The Phase 2 VIBRANT trial (NCT06164704) evaluated verekitug, a fully human monoclonal antibody targeting the TSLP receptor, in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). In this interview, Professor Joseph Han outlines the significant clinical burden of CRSwNP, explains the mechanism of action of verekitug, and discusses the rationale for the Phase 2 trial. Professor Han also reviews the trial’s design, objectives, and the key efficacy and safety findings, presented at AAAAI 2026.

Dr Amber Luong discusses results from the Phase 3 LIBERTY-AIMS trial of dupilumab in allergic fungal rhinosinusitis (AFRS), presented at AAAAI 2026, highlighting key efficacy findings and mechanism of action. These data are particularly timely given the recent FDA approval of dupilumab for AFRS, which was supported by findings from the study.

The CHEST 2025 annual meeting brought together pulmonary, critical care, and sleep medicine experts to share emerging science, clinical insights, and forward-looking innovations shaping respiratory care. Through focused conversations with leaders across the field, these interviews highlight practical, practice-ready insights that clinicians can bring directly to patient care.

The 2025 American College of Allergy, Asthma & Immunology (ACAAI; November 6−10, Orlando, Florida, USA) annual meeting showcased emerging therapies and real-world insights across eosinophilic disorders, atopic disease, chronic respiratory conditions, and allergic rhinitis. From late-breaking clinical trial results to observational data, the conference highlighted advances in convenient, effective, and targeted therapies for patients, as well as strategies to optimize long-term disease management.

Allergic rhinitis is a common and often underdiagnosed condition that can impact asthma control, sleep, and daily functioning. In this Q&A, Dr Syed Shahzad Mustafa discusses his CHEST 2025 presentation, reviewing first-line therapies, allergen avoidance strategies, and the evolving role of immunotherapy and biologics, offering practical guidance for clinicians to optimize patient care in 2025.

EUFOREA has expanded its Patient Portal to include asthma, offering reliable, expert-backed resources for people living with chronic respiratory diseases (CRDs) such as asthma, chronic rhinosinusitis (CRS), and COPD. In this Q&A, Dr. Sophie Scheire, EUFOREA’s Patient Education Manager, discusses how the portal helps bridge the knowledge gap, combat misinformation, and empower patients to take charge of their health, while also supporting healthcare professionals in providing better care.

As touchRESPIRATORY approaches 10 years of providing education for busy respiratory specialists, we are looking to the future—and it certainly looks bright!

As part of our EAACI 2025 coverage, we spoke with Dr Eugenio De Corso (Catholic University of the Sacred Heart, Milan) around the EVEREST trial, a phase 4 head-to-head study comparing dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. Dr De Corso explores the study’s methodology, key findings, and implications for clinical practice in managing this challenging patient population.